Cardiovascular organ damage in relation to hypertension status in patients with ankylosing spondylitis

Ullensvang, Gyda; Kringeland, Ester; Ikdahl, Eirik; Provan, Sella Aarrestad; Berg, I.J.; Rollefstad, Silvia; Dagfinrud, Hanne; Gerdts, Eva; Semb, A.G.; Midtbø, Helga

doi:10.1080/08037051.2023.2205956

Cited by 3 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surprisingly, there is little but conflicting data regarding the prevalence of hypertension in axSpA patients, yet, several studies showed higher risk for hypertension among AS patients [ 8 , 33 ] and a high risk of organ damage [ 34 , 35 ]. In fact, longer disease duration—especially more than 5 years—and delay in diagnosis seem to be major risk factors for hypertension according to a large ( n = 413, male = 77.2%) longitudinal cohort study from Shi et al Additionally, recurrent rise in erythrocyte sedimentation rate (ESR) was also associated with hypertension highlighting the role of inflammation in developing hypertension.…”

Section: Resultsmentioning

confidence: 99%

Cardiovascular risk in axial spondyloarthritis—a systematic review

Hintenberger,

Affenzeller,

Vladychuk

et al. 2023

Clin Rheumatol

View full text Add to dashboard Cite

Cardiovascular manifestations are common in patients suffering axial spondyloarthritis and can result in substantial morbidity and disease burden. To give an overview of this important aspect of axial spondyloarthritis, we conducted a systematic literature search of all articles published between January 2000 and 25 May 2023 on cardiovascular manifestations. Using PubMed and SCOPUS, 123 out of 6792 articles were identified and included in this review. Non-radiographic axial spondyloarthritis seems to be underrepresented in studies; thus, more evidence for ankylosing spondylitis exists. All in all, we found some traditional risk factors that led to higher cardiovascular disease burden or major cardiovascular events. These specific risk factors seem to be more aggressive in patients with spondyloarthropathies and have a strong connection to high or long-standing disease activity. Since disease activity is a major driver of morbidity, diagnostic, therapeutic, and lifestyle interventions are crucial for better outcomes. Key Points• Several studies on axial spondyloarthritis and associated cardiovascular diseases have been conducted in the last few years addressing risk stratification of these patients including artificial intelligence.• Recent data suggest distinct manifestations of cardiovascular disease entities among men and women which the treating physician needs to be aware of.• Rheumatologists need to screen axial spondyloarthritis patients for emerging cardiovascular disease and should aim at reducing traditional risk factors like hyperlipidemia, hypertension, and smoking as well as disease activity.

show abstract

Section: Resultsmentioning

confidence: 99%

Cardiovascular risk in axial spondyloarthritis—a systematic review

Hintenberger,

Affenzeller,

Vladychuk

et al. 2023

Clin Rheumatol

View full text Add to dashboard Cite

show abstract

Factors associated with change in arterial stiffness in patients with rheumatoid arthritis: the JointHeart study

Linde,

Gerdts,

Fevang

et al. 2024

Blood Pressure

View full text Add to dashboard Cite

Ankylosing spondylitis and cardiovascular disease: A two-sample Mendelian randomization analysis

Chen,

Hong,

Wang

et al. 2024

Medicine

View full text Add to dashboard Cite

Epidemiological research has demonstrated that people suffering from ankylosing spondylitis (AS) have a greater chance of developing cardiovascular disease (CVD), though the potential link between AS genetics and CVD risk is uncertain. This research examined the potential link between CVD outcomes and AS which is genetically determined. A two-sample Mendelian randomization analysis was conducted using data from European population genome-wide association study of AS and CVD. We selected single nucleotide polymorphisms closely associated with AS genetic susceptibility as instrumental variables, and used inverse variance weighted as the main method to analyze the causal effects of AS on 7 CVDs (heart failure, atrial fibrillation, hypertension, ischemic stroke, etc). To further reinforce our results, we conducted replication analyses, sensitivity analyses, and instrumental variable strength assessments. In the European population, it was observed that AS genetic susceptibility was correlated with a higher risk of heart failure (odds ratios [OR] = 1.0128, 95% confidence intervals [CI]: 1.0037–1.0219, P = .0058), hypertension (OR = 1.0143, 95% CI: 1.0038–1.0248, P = .0073), and ischemic stroke (OR = 1.0151, 95% CI: 1.0049–1.0255, P = .0036). However, it was not associated with coronary heart disease, cardiomyopathy, valvular heart disease, or atrial fibrillation (all P > .05). A sensitivity analysis was conducted to validate the reliability of the results. Evidence from the European population has indicated a correlation between AS and heart failure, hypertension, and ischemic stroke. Further investigations should be conducted to explore the underlying mechanisms of action.

show abstract

Cardiovascular organ damage in relation to hypertension status in patients with ankylosing spondylitis

Cited by 3 publications

References 35 publications

Cardiovascular risk in axial spondyloarthritis—a systematic review

Cardiovascular risk in axial spondyloarthritis—a systematic review

Factors associated with change in arterial stiffness in patients with rheumatoid arthritis: the JointHeart study

Ankylosing spondylitis and cardiovascular disease: A two-sample Mendelian randomization analysis

Contact Info

Product

Resources

About